非洲猪瘟病毒疫苗研究现状

doi:10.16174/j.issn.1673-4645.2023.06.016

摘要/Abstract

摘要： 非洲猪瘟(African swine fever,ASF)是一种由非洲猪瘟病毒(African swine fever virus,ASFV)引发的急性、烈性、高度接触性动物传染病，主要在家猪和野猪之间传播，致死率极高，是当今全球养猪业的头号威胁性疫病。2018年，我国首次发生非洲猪瘟疫情，导致生猪年产量减少40%。近5年，我国大力推进了ASF疫苗的研制工作，并取得了很大突破。目前，从技术路线看，非洲猪瘟病毒基因缺失减毒活疫苗的研发最具有合理性。本文现对非洲猪瘟疫苗研究现状进行概述，以期为国内非洲猪瘟的预防和控制提供参考。

关键词: 生猪, 非洲猪瘟病毒, 疫苗, 细胞免疫, 基因型, 毒株

金贵兵, 杨丁, 金仕强, 邹仲航, 牟燕平, 古从伟, 杨倩. 非洲猪瘟病毒疫苗研究现状[J]. 中国猪业, 2023, 18(6): 73-81.

参考文献

[1] Zhou X, Li N, Luo Y, et al. Emergence of African swine fever in China, 2018[J]. Transboundary and Emerging Diseases, 2018, 65(6):1482-1484. [2] Dixon LK, Stahl K, Jori F, et al. African swine fever epidemiology and control[J]. Annual Review of Animal Biosciences, 2020, 8(1):221-246. [3] Greenwood B. The contribution of vaccination to global health: past, present and future[J]. Philosophical transactions of the Royal Society of London. Series B, Biological Sciences, 2014, 369(1645). doi: 10.1098/rstb.2013.0433. [4] 陈思骏, 赵南燕, 周显刚, 等. 泸州市市中区脊髓灰质炎后遗症调查[J]. 泸州医学院学报, 1989(1):81. [5] Yu WZ, Wen N, Zhang Y, et al. Poliomyelitis eradication in China: 1953-2012[J]. Journal of Infectious Diseases, 2014, 210(Suppl 1):S268-S274. [6] Dixon LK, Abrams CC, Bowick G, et al. African swine fever virus proteins involved in evading host defence systems[J]. Veterinary Immunology and Immunopathology, 2004, 100(3-4):117-134. [7] Faburay B. Genome plasticity of African swine fever virus: implications for diagnostics and live-attenuated vaccines[J]. Pathogens, 2022, 11(2):145. [8] Qu H, Ge S, Zhang Y, et al. A systematic review of genotypes and serogroups of African swine fever virus[J]. Virus Genes, 2022, 58(2): 77-87. [9] Blome S, Gabriel C, Beer M. Modern adjuvants do not enhance the efficacy of an inactivated African swine fever virus vaccine preparation[J]. Vaccine, 2014, 32(31):3879-3882. [10] Arias M, Torre ADL, Dixon L, et al. Approaches and perspectives for development of African swine fever virus vaccines[J]. Vaccines (Basel), 2017, 5(4):35. [11] Gonzalvo FRZ, Coll JM. Characterization of a soluble hemagglutinin induced in African swine fever virus-infected cells[J]. Virology, 1993, 196(2):769-777. [12] Ruiz-Gonzalvo F, Rodríguez F, Escribano JM. Functional and immunological properties of the baculovirus-expressed hemagglutinin of African swine fever virus[J]. Virology, 1996, 218(1):285-289. [13] Gómez-Puertas P， Rodríguez F， Oviedo JM, et al. Neutralizing antibodies to different proteins of African swine fever virus inhibit both virus attachment and internalization[J]. Journal of Virology, 1996, 70(8):5689-5694. [14] Gómez-Puertas P， Rodríguez F， Oviedo JM, et al. The African swine fever virus proteins p54 and p30 are involved in two distinct steps of virus attachment and both contribute to the antibody-mediated protective immune response[J]. Virology, 1998, 243(2):461-471. [15] Barderas MG, Rodríguez F, Gómez-Puertas P, et al. Antigenic and immunogenic properties of a chimera of two immunodominant African swine fever virus proteins[J]. Archives of Virology, 2001, 146(9):1681-1691. [16] Neilan JG， Zsak L， Lu Z, et al. Neutralizing antibodies to African swine fever virus proteins p30, p54, and p72 are not sufficient for antibody-mediated protection[J]. Virology, 2004, 319(2):337-342. [17] Oura CAL， Denyer MS， Takamatsu H, et al. In vivo depletion of CD8+ T lymphocytes abrogates protective immunity to African swine fever virus[J]. Journal of General Virology, 2005, 86(Pt9):2445-2450. [18] Argilaguet JM， Pérez-Martín E， Gallardo C, et al. Enhancing DNA immunization by targeting ASFV antigens to SLA-Ⅱ bearing cells[J]. Vaccine, 2011, 29(33):5379-5385. [19] Argilaguet JM, Pérez-Martín E, Nofrarías M, et al. DNA vaccination partially protects against African swine fever virus lethal challenge in the absence of antibodies[J]. PLoS ONE, 2012, 7(9):e40942. doi: 10.1371/journal.pone.0040942. [20] Lacasta A， Ballester, M， Monteagudo PL, et al. Expression library immunization can confer protection against lethal challenge with African swine fever virus[J]. Journal of Virology, 2014, 88(22):13322-13332. [21] Bosch CL, López E, Nava MJ, et al. Identification of promiscuous African swine fever virus T-cell determinants using a multiple technical approach[J]. Vaccines (Basel), 2021, 9(1):29. doi: 10.3390/vaccines9010029. [22] Bosch CL， López E， Collado J, et al. M448R and MGF505-7R: two African swine fever virus antigens commonly recognized by ASFV-specific T-cells and with protective potential[J]. Vaccines, 2021, 9(5):508. doi: 10.3390/vaccines9050508. [23] Argilaguet JM， Pérez-Martín E， López S, et al. BacMam immunization partially protects pigs against sublethal challenge with African swine fever virus[J]. Antiviral Research, 2013, 98(1):61-65. [24] Lokhandwala S, Waghela SD, Bray J, et al. Induction of robust immune responses in swine using a cocktail of adenovirus-vectored African swine fever virus antigens[J]. Clinical and Vaccine Immunology, 2016, 23(11):888-900. [25] Lokhandwala S, Waghela SD, Bray J, et al. Adenovirus-vectored novel African swine fever virus antigens elicit robust immune responses in swine[J]. PLoS ONE, 2017, 12(5):e0177007. doi: 10.1371/journal.pone.0177007. [26] Lopera-Madrid J， Osorio JE, He YQ, et al. Safety and immunogenicity of mammalian cell derived and modified vaccinia ankara vectored African swine fever subunit antigens in swine[J]. Veterinary Immunology and Immunopathology, 2017, 185:20-33. [27] Lokhandwala S, Petrovan V, Popescu L, et al. Adenovirus-vectored African swine fever virus antigen cocktails are immunogenic but not protective against intranasal challenge with Georgia 2007/1 isolate[J]. Veterinary Microbiology, 2019, 235:10-20. [28] Goatley LC，Reis AL， Portugal R, et al. A Pool of eight virally vectored African swine fever antigens protect pigs against fatal disease[J]. Vaccines, 2020, 8(2):234. doi: 10.3390/vaccines8020234. [29] Teklue T, Sun Y, Muhammad A, et al. Current status and evolving approaches to African swine fever vaccine development[J]. Transboundary and Emerging Diseases, 2020, 67(2):529-542. [30] Gallardo C, Sánchez EG, Pérez ND, et al. African swine fever virus (ASFV) protection mediated by NH/P68 and NH/P68 recombinant live-attenuated viruses[J]. Vaccine, 2018, 36(19): 2694-2704. [31] Leit?o A, Cartaxeiro C, Coelho R, et al. The non-haemadsorbing African swine fever virus isolate ASFV/NH/P68 provides a model for defining the protective anti-virus immune response[J]. Journal of General Virology, 2001, 82(3):513-523. [32] King K, Chapman D, Argilaguet JM, et al. Protection of European domestic pigs from virulent African isolates of African swine fever virus by experimental immunisation[J]. Vaccine, 2011, 29(28):4593-4600. [33] Mulumba LK, Goatley LC, Saegerman C, et al. Immunization of African indigenous pigs with attenuated genotypeⅠAfrican swine fever virus OURT88/3 induces protection against challenge with virulent strains of genotype I[J]. Transboundary and Emerging Diseases, 2016, 63(5):e323-e327. [34] Sánchez PJ, Chaoman D, Jabbar T, et al. Different routes and doses influence protection in pigs immunised with the naturally attenuated African swine fever virus isolate OURT88/3[J]. Antiviral Research, 2017, 138(Complete):1-8. [35] Gallardo C, Soler A, Rodze I, et al. Attenuated and non-haemadsorbing (non-HAD) genotypeⅡ African swine fever virus (ASFV) isolated in Europe, Latvia 2017[J]. Transboundary and Emerging Diseases, 2019, 66(3):1399-1404. [36] Barasona JA, Gallardo C, Cadenas FE, et al. First oral vaccination of Eurasian wild boar against African swine fever virus genotypeⅡ[J]. Frontiers in Veterinary Science, 2019, 6:137. [37] Sun E, Zhang Z, Wang Z, et al. Emergence and prevalence of naturally occurring lower virulent African swine fever viruses in domestic pigs in China in 2020[J]. Science China Life Science, 2021, 64(5):752-765. [38] 戈胜强, 张潇月, 吕艳, 等. 非洲猪瘟病毒细胞传代致弱株研究进展[J]. 中国动物检疫, 2021, 38(6):76-81. [39] 戈胜强 ,韩乃君, 吕艳, 等. 葡萄牙使用非洲猪瘟弱毒疫苗的历史案例分析[J]. 中国动物检疫, 2021, 38(8):57-62. [40] Krug PW, Holinka LG, O'donnell V, et al. The Progressive adaptation of a Georgian isolate of African swine fever virus to vero cells leads to a gradual attenuation of virulence in swine corresponding to major modifications of the viral genome[J]. Journal of Virology, 2015, 89(4):2324-2332. [41] Balysheva VI, Prudnikova EY, Galnbek TV, et al. Immunological properties of attenuated variants of African swine fever virus isolated in the Russian federation[J]. Russian Agricultural Sciences, 2015, 41(2-3):178-182. [42] Tulman ER, Rock DL. Novel virulence and host range genes of African swine fever virus[J]. Current Opinion in Microbiology, 2001, 4(4):456-461. [43] Lewis T, Zsak L, Burrage TG, et al. An African swine fever virus ERV1-ALR homologue, 9GL, affects virion maturation and viral growth in macrophages and viral virulence in swine[J]. Journal of Virology, 2000, 74(3):1275-1285. [44] Moore DM, Zsak L, Neilan JG, et al. The African swine fever virus thymidine kinase gene is required for efficient replication in swine macrophages and for virulence in swine[J]. Journal of Virology, 1998, 72(12):10310-10315. [45] Golding JP, Goatley L, Goodbourn S, et al. Sensitivity of African swine fever virus to typeⅠinterferon is linked to genes within multigene families 360 and 505[J]. Virology, 2016, 493:154-161. [46] O'donnell V, Holinka LG, Gladue DP, et al. African swine fever virus Georgia isolate harboring deletions of MGF360 and MGF505 genes is attenuated in swine and confers protection against challenge with virulent parental virus[J]. Journal of Virology, 2015, 89(11):6048-6056. [47] O'donnell V, Holinka LG, Krug PW, et al. African swine fever virus Georgia 2007 with a deletion of virulence-associated gene 9GL (B119L), when administered at low doses, leads to virus attenuation in swine and induces an effective protection against homologous challenge[J]. Journal of Virology, 2015, 89(16):8556-8566. [48] O'donnell V, Risatti GR, Holinka LG, et al. Simultaneous deletion of the 9GL and UK genes from the African swine fever virus georgia 2007 isolate offers increased safety and protection against homologous challenge[J]. Journal of Virology, 2017, 91(1):1760-1776. [49] Monteagudo PL, Lacasta A, López E, et al. BA71ΔCD2: a new recombinant live attenuated African swine fever virus with cross-protective capabilities[J]. Journal of Virology, 2017, 91(21):1158-1167. [50] Lopez E, Van Heerden J, Bosch CL, et al. Live attenuated African swine fever viruses as ideal tools to dissect the mechanisms involved in cross-protection[J]. Viruses, 2020, 12(12):1474. [51] Borca MV, O'donnell V, Holinka LG, et al. Deletion of CD2-like gene from the genome of African swine fever virus strain Georgia does not attenuate virulence in swine[J]. Scientific Reports, 2020, 10(1):494. [52] Neilan JG, Zsak L, Lu Z, et al. Novel swine virulence determinant in the left variable region of the African swine fever virus genome[J]. Journal of Virology, 2002, 76(7):3095-3104. [53] Afonso CL, Zsak L, Carrillo CC, et al. African swine fever virus NL gene is not required for virus virulence[J]. Journal of General Virology, 1998, 79(10):2543-2547. [54] Sanford B, Holinka LG, O'donnell V, et al. Deletion of the thymidine kinase gene induces complete attenuation of the Georgia isolate of African swine fever virus[J]. Virus Research, 2016, 213:165-171. [55] Moore DM, Zsak L, Neilan JG, et al. The African swine fever virus thymidine kinase gene is required for efficient replication in swine macrophages and for virulence in swine[J]. Journal of Virology, 1998, 72(12):10310-10315. [56] Abrams CC, Goatley L, Fishbourne E, et al. Deletion of virulence associated genes from attenuated African swine fever virus isolate OUR T88/3 decreases its ability to protect against challenge with virulent virus[J]. Virology, 2013, 443(1):99-105. [57] Gladue DP, O'donnell V, Ramirez ME, et al. Deletion of CD2-like (CD2v) and C-type lectin-like(EP153R) genes from African swine fever virus Georgia-?9GL abrogates its effectiveness as an experimental vaccine[J]. Viruses, 2020, 12(10):1185. [58] O'donnell V, Holinka LG, Sanford B, et al. African swine fever virus Georgia isolate harboring deletions of 9GL and MGF360/505 genes is highly attenuated in swine but does not confer protection against parental virus challenge[J]. Virus Research, 2016, 221:8-14. [59] Ramirez ME, Vuono E, O'donnell V, et al. Differential effect of the deletion of African swine fever virus virulence-associated genes in the induction of attenuation of the highly virulent Georgia strain[J]. Viruses, 2019, 11(7):599. doi: 10.3390/v11070599. [60] Chen W, Zhao D, He X, et al. A seven-gene-deleted African swine fever virus is safe and effective as a live attenuated vaccine in pigs[J]. Science China Life Sciences, 2020, 63(5):623-634. [61] Borca MV, Ramirez ME, Silva E, et al. Development of a highly effective African swine fever virus vaccine by deletion of the I177L gene results in sterile immunity against the current epidemic Eurasia strain[J]. Journal of Virology, 2020, 94(7):e02017-19. doi: 10.1128/JVI.02017-19. [62] Borca MV, Ramirez ME, Silva E, et al. ASFV-G-?I177L as an effective oral nasal vaccine against the Eurasia strain of Africa swine fever[J]. Viruses, 2021, 13(5):765. doi: 10.3390/v13050765. [63] Borca MV, Rai A, Ramirez ME, et al. A cell culture-adapted vaccine virus against the current African swine fever virus pandemic strain[J]. Journal of Virology, 2021, 95(14):e0012321. doi: 10.1128/JVI.00123-21. [64] Tran XH, Le TTP, Nguyen QH, et al. African swine fever virus vaccine candidate ASFV-G-ΔI177L efficiently protects European and native pig breeds against circulating Vietnamese field strain[J]. Transboundary and Emerging Diseases, 2022, 69(4):e497-e504.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed